
Respiree
Providing Targeted Predictions and Diagnosis Using Breath-Cardio Informatics.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor investor investor investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | $11.6m | Series A | |
Total Funding | 000k |
USD | 2022 |
---|---|
Revenues | 0000 |
EBITDA | 0000 |
Profit | 0000 |
EV | 0000 |
EV / revenue | 00.0x |
EV / EBITDA | 00.0x |
R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Respiree is a healthcare technology company specializing in advanced breath cardio sensors and artificial intelligence to provide targeted predictions and diagnoses of cardio-respiratory diseases. The company serves hospitals, pharmaceutical companies, and academic institutions by offering a centralized platform, the Breath Cardio Engine, which tracks and predicts patient decompensation, readmissions, and compliance. Respiree operates in the healthcare market, focusing on improving patient outcomes and the overall quality of medicine. The business model revolves around selling its predictive analytics platform and sensor technology to its clients, generating revenue through subscriptions and service fees. Respiree has been recognized in various prestigious programs, including the Hello Tomorrow Global Summit and the General Electric GE Accelerator Program.
Keywords: breath cardio sensors, AI, predictive healthcare, patient outcomes, hospitals, pharmaceutical companies, academic institutions, decompensation tracking, readmission prediction, compliance monitoring.